Neurocrine Biosciences | Spese Di Vendita E Di Amministrazione





Spese Di Vendita E Di Amministrazione Cambiamento Data
AbbVie USD 3.89B 325M 2025-12
Acadia Pharmaceuticals USD 124.9M 1.24M 2025-09
Agios Pharmaceuticals USD 42.97M 1.7M 2025-12
ALKERMES USD 171.77M 17.9M 2025-09
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Amgen USD 1.94B 237M 2025-12
Biogen USD 545.2M 38.6M 2025-09
BioMarin Pharmaceutical USD 223.42M 8.86M 2025-09
Cytokinetics USD 158.75M 93.03M 2025-09
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Exelixis USD 123.02M 19.9M 2025-12
Gilead Sciences USD 1.78B 425M 2025-12
Halozyme Therapeutics USD 64.64M 27.11M 2025-12
Incyte USD 390.41M 61.33M 2025-12
Ionis Pharmaceuticals USD 86.56M 4.04M 2025-09
Nektar Therapeutics USD -0.18 0.07 2024-09
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Pfizer USD 4.08B 894M 2025-12
Prothena USD 13.24M 2.67M 2025-09
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Repligen USD 73.66M 2.43M 2025-09
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sarepta Therapeutics USD 77.11M 7.22M 2025-09
Teva Pharmaceutical Industries USD 1.12B 147M 2025-12
Ultragenyx Pharmaceutical USD 89M 2.38M 2025-12
Vertex Pharmaceuticals USD 487M 41.9M 2025-12
Xoma USD 11M 2.54M 2024-06


Neurocrine Biosciences Spese Di Vendita E Di Amministrazione - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.